Skip to main content
letter
. 2020 Aug 14;137(21):2997–3001. doi: 10.1182/blood.2020008635

Table 1.

Baseline characteristics of patients with SCD and controls

Patients with SCD* (n = 22) Controls (n = 10)
Patient-related features
 Sex, female, n (%) 9 (40.9) 9 (90.0)
 Age, y 23 (7-57) 48 (26-63)
 α-Thalassemia, n (%) 3 (13.6) N/D
 Splenectomy, n (%) 1 (4.5) N/D
 HU, n (%) 13 (59.1) N/D
 Chronic transfusion, n (%) 0 (0.0) N/D
Red cell features
 HbF, % 7.4 (0.6-28.8) 0.5 (0.4-0.6)
 HbS, % 81.3 (59.4-89.3) 0.0 (0.0-0.0)
 Hb, g/dL 9.4 (7.1-12.3) 14.5 (12.3-17.4)
 Reticulocytes, % 9.1 (4.0-21.9) 1.4 (0.7-2.3)
 RBC count, 1012/L 2.9 (2.2-4.4) 4.7 (3.7-5.4)
 MCV, fl 82.3 (69.4-125) 92.7 (83.8-105)
 MCHC, g/dL 34.9 (33.4-38.2) 34.4 (31.9-37.5)
PK features
 PK activity, U/gHb 13.7 (7.5-22.4) 7.9 (5.3-8.7)
 HK activity, U/gHb 2.6 (1.2-4.9) 0.8 (0.5-1.0)
 PK/HK ratio 5.1 (2.5-9.9) 8.9 (7.4-14.0)
 PK-thermostability, % residual activity 54.9 (35.8.2-80.8) 76.3 (72.6-80.9)
 PK protein, AU/gHb 146 (105-176) 102 (78-124)
 PKLR mutations None detected N/D
Metabolic features*
 2,3-DPG, 10−3 μg/gHb 4.6 (3.5-6.3) 3.3 (2.8-4.1)
 ATP, 10−3 μg/gHb 2.0 (1.9-3.0) 2.0 (1.6-2.5)
 ATP/2,3-DPG ratio 0.44 (0.34-0.67) 0.57 (0.46-0.81)

Numbers represent median (range) unless stated otherwise.

HU, hydroxyurea; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; N/D, not determined.

*

Metabolic features were obtained from 14/22 patients with SCD.

P < .0001.

P < .01.